Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

432P - Determinants of pre-surgical treatment in primary rectal cancer: A population-based study

Date

10 Sep 2022

Session

Poster session 08

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Israa Imam

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

I. Imam1, K. Hammarström1, B. Glimelius2

Author affiliations

  • 1 Department Of Immunology, Genetics And Pathology, Uppsala University, 75185 - Uppsala/SE
  • 2 Department Of Immunology, Genetics And Pathology, University Hospital Uppsala/Akademiska Sjukhuset, 75185 - Uppsala/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 432P

Background

Preoperative radiotherapy (RT) is frequently used in rectal cancer to improve results, but when it is best used alone or with chemotherapy (CT) is subject to discussions and guidelines differ. To better understand selection mechanisms in a changing landscape, we analysed chosen initial treatment in all patients diagnosed during an eleven-years period in two Swedish regions, one with and one without a RT-department.

Methods

All patients with rectal cancer in Uppsala (with a RT department) and Dalarna, between 2010-2020 were prospectively identified. Information on staging and initial treatment (direct surgery, preoperative short-course RT or combinations of RT and CT) in the Swedish Colorectal Cancer Registry were used. Information from the staging magnetic resonance imaging (MRI) permitted division into three risk groups, early/good, intermediate/bad and locally advanced/ugly according to the national guidelines for treatment recommendations during the period. Cohen’s kappa was used to test congruence between clinical and pathologic stage, and logistic regression to explore associations between baseline characteristics and treatment choice.

Results

1150 patients without synchronous metastases (M0) were analysed (Uppsala 542, Dalarna 608). Patients from Dalarna were older, had less advanced tumours and received presurgical treatment less often (63% vs 52%, p<0.001). All MRI-characteristics (T-/N-stage, MRF, EMVI, tumour level) were important for treatment choice but not age and sex. Age was, however, important for if CT was added. Independent associations were seen for all MRI-characteristics, but not for region. The treatment choices followed the recommendations in the good and ugly groups but varied in the bad group. The correlation between clinical and pathological T-stage was fair/moderate and poor for N-stage.

Conclusions

The risk grouping based on MRI-characteristics had the most influence on treatment choice. Since the risk grouping was modified, due to a wish to diminish the proportion pre-treated, fewer patients were irradiated with time. Regional differences in interpretation of the MRI characteristics probably explained that fewer patients were pre-treated in Dalarna. MRI-staging is far from optimal.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Cancerfonden (Swedish Cancer Society).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.